Clinical trial · Interventional
Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors
A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
Summary
Brief summary (as posted)
This is a multi-centre Phase 2 study. The study will evaluate the activity and safety of AMG 337 in patients who have MET amplified gastric, gastroesophageal junction or esophageal adenocarcinoma or other MET amplified solid tumors. The study is designed to estimate the objective response rate of AMG 337 by tumor type.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stomach Neoplasms | Gastric Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AMG 337 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Single arm
- description
- AMG 337 Monotherapy
- interventionNames
- Drug: AMG 337
Primary outcomes (1)
- measure
- Objective Response Rate (RECIST v1.1) in subjects with MET Amplified measurable G/GEJ/E adenocarcinoma (Cohort 1)
- timeFrame
- 2.5 years
- description
- Determine antitumor activity of AMG 337 in subjects with MET amplified G/GEJ/E adenocarcinoma
Secondary outcomes (8)
- measure
- Duration of response (cohort 1 and subjects with measurable disease at baseline in cohort 2)
- timeFrame
- 2.5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Able to daily self-administer AMG 337 orally as a whole capsule * Male or female 18 years of age or over. * Pathologically confirmed advanced G/GEJ/E adenocarcinoma (Cohort 1) or other solid tumor (Cohort 2) for which subject has received prior therapy for advanced disease, for which no standard therapy exists, or subject refuses standard therapy * Tumor MET amplified by protocol-specified centralized testing. * Measurable disease per RECIST 1.1 guidelines. Cohort 2 may include up to 10 subjects with advanced MET amplified, G/GEJ/E adenocarcinoma with non-measurable tumor per RECIST v1.1 * (ECOG) Performance Status of 0, 1 or 2 Exclusion Criteria: * Known central nervous system metastases * Candidate for curative surgery or definitive chemoradiation * Peripheral edema \> grade 1 * Persistent gastric outlet obstruction, complete dysphagia or are dependent upon jejunostomy for feeding. Significant gastrointestinal disorder(s) that in the opinion of the Investigator may influence drug absorption * Acute Hepatitis B. Chronic Hepatitis B eligible if condition is stable and, in the opinion of the investigator or Amgen physician, if consulted, would not pose a risk to subject safety * Detectable Hepatitis C virus (indicative of active Hepatitis C) * Currently receiving any anti-tumor treatments, or less than 14 days prior to enrollment since ending anti-tumor treatment * Prior treatment with small molecule inhibitors of the MET pathway. Other protocol defined inclusion criteria may apply.
References
Publications (0)
Data not yet available